Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Edesa Biotech ( (EDSA) ) is now available.
On September 9, 2025, Edesa Biotech, Inc. filed a prospectus supplement with the SEC for an ‘at the market offering’ program, allowing the sale of up to $4,006,544 of common shares through H.C. Wainwright & Co., LLC. The company has already sold $837,134 worth of shares under this agreement, and the legal opinion validating the offering was issued by Fasken Martineau DuMoulin LLP.
The most recent analyst rating on (EDSA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.
Spark’s Take on EDSA Stock
According to Spark, TipRanks’ AI Analyst, EDSA is a Underperform.
Edesa Biotech exhibits significant financial challenges, reflected in zero revenue and persistent losses, severely impacting its overall score. Technical indicators show a stable market position, but poor valuation metrics further weigh down the stock’s attractiveness. The lack of revenue and cash flow sustainability poses significant risks.
To see Spark’s full report on EDSA stock, click here.
More about Edesa Biotech
Edesa Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative treatments for inflammatory and immune-related diseases.
Average Trading Volume: 23,303
Technical Sentiment Signal: Sell
Current Market Cap: $17.81M
See more data about EDSA stock on TipRanks’ Stock Analysis page.